$35 Mil. Timm Medical Acquisition Broadens Endocare Urology Market
This article was originally published in The Gray Sheet
Executive Summary
Endocare's Feb. 21 acquisition of Timm Medical Technolgies provides a much-enlarged customer base for its urology product offering
You may also be interested in...
Cryoablation Or Brachytherapy? Endocare Promotes Prostate First-Line Option
Endocare is hoping that the results of an eight-year 590-patient registry study will convince more urologists to use cryoablation as an alternative to brachytherapy for first-line treatment of prostate cancer
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.